Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 56,254 |
|
|||||
| News | - | ||||||
| Day High | 1.797 | Low High |
|||||
| Day Low | 1.67 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Equillium Inc | EQ | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.02 | -1.12% | 1.77 | 13:07:50 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.78 | 1.67 | 1.797 | 1.79 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 211 | 56,254 | $ 1.73 | $ 97,182 | - | 0.45 - 3.25 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 13:20:43 | 1 | $ 1.77 | USD |
Equillium Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 62.16M | 35.12M | - | 36.08M | -13.34M | -0.38 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Equillium News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical EQ Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.76 | 1.84 | 1.58 | 1.70 | 85,660 | 0.01 | 0.57% |
| 1 Month | 2.04 | 2.45 | 1.58 | 2.03 | 137,916 | -0.27 | -13.24% |
| 3 Months | 0.8289 | 3.25 | 0.799 | 1.99 | 391,303 | 0.9411 | 113.54% |
| 6 Months | 0.5525 | 3.25 | 0.45 | 1.58 | 259,388 | 1.22 | 220.36% |
| 1 Year | 0.6163 | 3.25 | 0.45 | 1.26 | 207,145 | 1.15 | 187.20% |
| 3 Years | 6.21 | 7.75 | 0.45 | 2.27 | 140,244 | -4.44 | -71.50% |
| 5 Years | 5.29 | 30.20 | 0.45 | 14.64 | 410,543 | -3.52 | -66.54% |
Equillium Description
| Equillium Inc is a biotechnology developing therapies to treat autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph 2 ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease. |
